VIA
TGTX icon

Vantage Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Vantage Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-150
Closed -$2K – 809
2018
Q2 		$2K Hold
150
– – ﹤0.01% 707
2018
Q1 		$2K Buy
+150
New +$1.92K ﹤0.01% 749

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM

Vantage Investment Advisors's TGTX Position: Q3 2018 in Review

Vantage Investment Advisors sold out of TG Therapeutics (TGTX) in Q3 2018, closing a stake of 150 shares — an estimated $2K sold.

Vantage Investment Advisors first reported a position in TGTX in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q2 2018. 127 funds tracked by Wall St. Rank hold TGTX as of Q3 2018.

  • Vantage Investment Advisors reported no remaining TG Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Vantage Investment Advisors sold 150 TG Therapeutics shares in Q3 2018, an estimated $2K.
  • Vantage Investment Advisors first reported a position in TG Therapeutics in Q1 2018 and held it in 2 quarters.
  • Vantage Investment Advisors's TG Therapeutics position peaked at $2K in Q2 2018.
  • 127 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.